We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+15.25%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$133M
AUM Growth
+$5.69M
Cap. Flow
+$3.69M
Cap. Flow %
2.77%
Top 10 Hldgs %
72.54%
Holding
56
New
1
Increased
8
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$1.79M
2
STOK icon
Stoke Therapeutics
STOK
+$745K
3
IMGN
Immunogen Inc
IMGN
+$472K
4
AXGN icon
Axogen
AXGN
+$373K
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$365K

Top Sells

Rank Stock Value
1
HROW icon
Harrow
HROW
+$660K
2
IFRX icon
InflaRx
IFRX
+$89.5K
3
NKTR icon
Nektar Therapeutics
NKTR
+$64K
4
ELTX icon
Elicio Therapeutics
ELTX
+$32K
5
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$22K

Sector Composition

Rank Sector Weight
1 Healthcare 96.02%
2 Energy 3.95%
3 Consumer Staples 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
26
Stoke Therapeutics
STOK
$1.74B
$904K 0.68%
85,000
+70,000
+467% +$745K
VTYX
27
DELISTED
Ventyx Biosciences
VTYX
$866K 0.65%
26,400
– –
BLUE
28
DELISTED
bluebird bio
BLUE
$820K 0.61%
12,460
+2,500
+25% +$183K
CYTK icon
29
Cytokinetics
CYTK
$10.9B
$816K 0.61%
25,000
– –
PXD
30
DELISTED
Pioneer Natural Resource Co.
PXD
$787K 0.59%
3,800
– –
TXG icon
31
10x Genomics
TXG
$5.49B
$670K 0.5%
12,000
+2,000
+20% +$108K
SILK
32
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$650K 0.49%
20,000
+10,000
+100% +$365K
TVTX icon
33
Travere Therapeutics
TVTX
$5.18B
$614K 0.46%
40,000
+10,000
+33% +$182K
TSVT
34
DELISTED
2seventy bio
TSVT
$606K 0.45%
59,833
– –
KDNY
35
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$576K 0.43%
15,000
– –
KPTI icon
36
Karyopharm Therapeutics
KPTI
$150M
$521K 0.39%
19,422
– –
KNSA icon
37
Kiniksa Pharmaceuticals
KNSA
$4.83B
$422K 0.32%
30,000
– –
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.5B
$385K 0.29%
10,000
– –
ARVN icon
39
Arvinas
ARVN
$517M
$372K 0.28%
15,000
– –
AXGN icon
40
Axogen
AXGN
$2.09B
$365K 0.27%
+40,000
New +$373K
HALO icon
41
Halozyme
HALO
$9.21B
$361K 0.27%
10,000
– –
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
$360K 0.27%
40,000
– –
PGNY icon
43
Progyny
PGNY
$2.51B
$354K 0.27%
9,000
– –
FOLD
44
DELISTED
Amicus Therapeutics
FOLD
$352K 0.26%
28,000
– –
XNCR icon
45
Xencor
XNCR
$1.4B
$307K 0.23%
12,300
– –
SRPT icon
46
Sarepta Therapeutics
SRPT
$1.81B
$286K 0.21%
2,500
– –
KROS icon
47
Keros Therapeutics
KROS
$210M
$281K 0.21%
7,000
– –
CGEM icon
48
Cullinan Oncology
CGEM
$1.09B
$270K 0.2%
25,114
– –
IFRX icon
49
InflaRx
IFRX
$271M
$223K 0.17%
50,000
-20,000
-29% -$89.5K
BCRX icon
50
BioCryst Pharmaceuticals
BCRX
$2.34B
$141K 0.11%
20,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Birchview Capital held 56 positions worth $133M, up 4.5% from $128M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Birchview Capital's Q2 2023 filing shows 1 new, 8 increased, 3 reduced and 2 closed positions. Its largest new stake was Axogen: 40,000 shares worth $365K. The largest sale was Harrow, an estimated $660K.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2023 buy was Axogen: 40,000 shares worth $365K.
  • Birchview Capital added most to Prothena Corp in Q2 2023, an estimated $1.79M increase.
  • Birchview Capital's biggest Q2 2023 reduction was Harrow, cutting an estimated $660K.
  • Birchview Capital fully exited Elicio Therapeutics in Q2 2023, selling an estimated $32K.
  • Birchview Capital's ten largest holdings make up 73% of its $133M portfolio in Q2 2023.
  • Birchview Capital opened 1 new position and closed 2 in Q2 2023.
  • Birchview Capital's portfolio value rose 4.5% quarter-over-quarter to $133M.

Based on Birchview Capital's 13F filing for Q2 2023, filed 8 Aug 2023.